

25. Iannuzzi-Sucich M, Prestwood KM, Kenny AM. Prevalence of sarcopenia and predictors of skeletal muscle mass in healthy, older men and women. *J Gerontol A Biol Sci Med Sci* 2002;57:M772–M777.
26. Lau EM, Lynn HS, Woo JW, et al. Prevalence of and risk factors for sarcopenia in elderly Chinese men and women. *J Gerontol A Biol Sci Med Sci* 2005;60:213–216.
27. Maggio M, Lauretani F, Ceda GP. Sex hormones and sarcopenia in older persons. *Curr Opin Clin Nutr Metab Care* 2013;16:3–13.
28. Auyeung TW, Lee JS, Kwok T, et al. Testosterone but not estradiol level is positively related to muscle strength and physical performance independent of muscle mass: A cross-sectional study in 1489 older men. *Eur J Endocrinol* 2011;164:811–817.
29. Dey DK, Bosaeus I, Lissner L, Steen B. Changes in body composition and its relation to muscle strength in 75-year-old men and women: A 5-year prospective follow-up study of the NORA cohort in Goteborg, Sweden. *Nutrition* 2009;25:613–619.
30. Auyeung TW, Lee JS, Leung J, et al. Adiposity to muscle ratio predicts incident physical limitation in a cohort of 3153 older adults—an alternative measurement of sarcopenia and sarcopenic obesity. *Age (Dordr)* 2013;35:1377–1385.
31. Chen CY. Meeting the challenges of eldercare in Taiwan's aging society. *J Clin Gerontol Geriatr* 2010;1:2–4.
32. Woo J. Meeting the needs of an ageing population in China: Public health and policy implications. *J Clin Gerontol Geriatr* 2013;4:31–32.
33. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. *Age Ageing* 2010;39:412–423.
34. Morley JE. Sarcopenia: Diagnosis and treatment. *J Nutr Health Aging* 2008;12:452–456.
35. Fielding RA, Vellas B, Evans WJ, et al. Sarcopenia: An undiagnosed condition in older adults. Current consensus definition: Prevalence, etiology, and consequences. International working group on sarcopenia. *J Am Med Dir Assoc* 2011;12:249–256.
36. Lexell J, Taylor CC, Sjostrom M. What is the cause of the ageing atrophy? Total number, size and proportion of different fiber types studied in whole vastus lateralis muscle from 15- to 83-year-old men. *J Neurol Sci* 1988;84:275–294.
37. Frontera WR, Hughes VA, Fielding RA, et al. Aging of skeletal muscle: A 12-year longitudinal study. *J Appl Physiol* 2000;88:1321–1326.
38. Waters DL, Baumgartner RN, Garry PJ. Sarcopenia: Current perspectives. *J Nutr Health Aging* 2000;4:133–139.
39. Chien MY, Huang TY, Wu YT. Prevalence of sarcopenia estimated using a bioelectrical impedance analysis prediction equation in community-dwelling elderly people in Taiwan. *J Am Geriatr Soc* 2008;56:1710–1715.
40. Nigam P, Misra A, Colles SL. Comparison of DEXA-derived body fat measurement to two race-specific bioelectrical impedance equations in healthy Indians. *Diabetes Metab Syndr* 2013;7:72–77.
41. Mijnders DM, Meijers JM, Halfens RJ, et al. Validity and reliability of tools to measure muscle mass, strength, and physical performance in community-dwelling older people: A systematic review. *J Am Med Dir Assoc* 2013;14:170–178.
42. Janssen I, Heymsfield SB, Baumgartner RN, Ross R. Estimation of skeletal muscle mass by bioelectrical impedance analysis. *J Appl Physiol* 2000;89:465–471.
43. Yamada Y, Watanabe Y, Ikenaga M, et al. Comparison of single- or multi-frequency bioelectrical impedance analysis and spectroscopy for assessment of appendicular skeletal muscle in the elderly. *J Appl Physiol* 2013;115:812–818.
44. Kim M, Kim H. Accuracy of segmental multi-frequency bioelectrical impedance analysis for assessing whole-body and appendicular fat mass and lean soft tissue mass in frail women aged 75 years and older. *Eur J Clin Nutr* 2013;67:395–400.
45. Yeh CW, Chen YJ, Lai LY, et al. Bioelectrical impedance analysis in a mathematical model for estimating fat-free mass in multiple segments in elderly Taiwanese males. *Int J Gerontol* 2012;6:273–277.
46. Strasser EM, Draskovits T, Prashak M, et al. Association between ultrasound measurements of muscle thickness, pennation angle, echogenicity and skeletal muscle strength in the elderly. *Age (Dordr)* 2013;35:2377–2388.
47. Lee WJ, Liu LK, Peng LN, et al. Comparisons of sarcopenia defined by IWGS and EWGSOP criteria among older people: Results from the I-Lan longitudinal aging study. *J Am Med Dir Assoc* 2013;14:528.e1–528.e7.
48. Kim YS, Lee Y, Chung YS, et al. Prevalence of sarcopenia and sarcopenic obesity in the Korean population based on the Fourth Korean National Health and Nutritional Examination Surveys. *J Gerontol A Biol Sci Med Sci* 2012;67:1107–1113.
49. Wu SW, Wu SF, Liang HW, et al. Measuring factors affecting grip strength in a Taiwan Chinese population and a comparison with consolidated norms. *Appl Ergon* 2009;40:811–815.
50. Liu LK, Lee WJ, Liu CL, et al. Age-related skeletal muscle mass loss and physical performance in Taiwan: Implications to diagnostic strategy of sarcopenia in Asia. *Geriatr Gerontol Int* 2013;13:964–971.
51. Functional outcomes for clinical trials in frail older persons. Time to be moving. *J Gerontol A Biol Sci Med Sci* 2008;63:160–164.
52. Guralnik JM, Ferrucci L, Pieper CF, et al. Lower extremity function and subsequent disability: Consistency across studies, predictive models, and value of gait speed alone compared with the short physical performance battery. *J Gerontol A Biol Sci Med Sci* 2000;55:M221–M231.
53. Cesari M, Kritchevsky SB, Newman AB, et al. Added value of physical performance measures in predicting adverse health-related events: Results from the Health, Aging And Body Composition Study. *J Am Geriatr Soc* 2009;57:251–259.
54. Liu LK, Peng LN, Chen LY, et al. Timed Up-and-Go Test: A potential indicator for successful aging of older men in Taiwan. *J Aging Res Clin Practice* 2013;2:152–156.
55. Chen L. Sarcopenia: Have we reached the consensus? *J Frailty Aging* 2012;1:99–101.
56. Arango-Lopera VE, Arroyo P, Gutierrez-Robledo LM, et al. Mortality as an adverse outcome of sarcopenia. *J Nutr Health Aging* 2013;17:259–262.
57. Harber MP, Konopka AR, Douglass MD, et al. Aerobic exercise training improves whole muscle and single myofiber size and function in older women. *Am J Physiol Regul Integr Comp Physiol* 2009;297:R1452–R1459.
58. McCartney N, Hicks AL, Martin J, Webber CE. Long-term resistance training in the elderly: Effects on dynamic strength, exercise capacity, muscle, and bone. *J Gerontol A Biol Sci Med Sci* 1995;50:B97–B104.
59. Liu CJ, Latham NK. Progressive resistance strength training for improving physical function in older adults. *Cochrane Database Syst Rev* 2009;3:CD002759.
60. Farinatti PT, Geraldes AA, Bottaro MF, et al. Effects of different resistance training frequencies on the muscle strength and functional performance of active women older than 60 years. *J Strength Cond Res* 2013;27:2225–2234.
61. Liu-Ambrose T, Khan KM, Eng JJ, et al. Resistance and agility training reduce fall risk in women aged 75 to 85 with low bone mass: A 6-month randomized, controlled trial. *J Am Geriatr Soc* 2004;52:657–665.
62. Morley JE, Argiles JM, Evans WJ, et al. Nutritional recommendations for the management of sarcopenia. *J Am Med Dir Assoc* 2010;11:391–396.
63. Rudman D, Feller AG, Nagraj HS, et al. Effects of human growth hormone in men over 60 years old. *N Engl J Med* 1990;323:1–6.
64. Brill KT, Weltman AL, Gentili A, et al. Single and combined effects of growth hormone and testosterone administration on measures of body composition, physical performance, mood, sexual function, bone turnover, and muscle gene expression in healthy older men. *J Clin Endocrinol Metab* 2002;87:5649–5657.
65. Papadakis MA, Grady D, Black D, et al. Growth hormone replacement in healthy older men improves body composition but not functional ability. *Ann Intern Med* 1996;124:708–716.
66. Wallymahmed ME, Foy P, Shaw D, et al. Quality of life, body composition and muscle strength in adult growth hormone deficiency: The influence of growth hormone replacement therapy for up to 3 years. *Clin Endocrinol* 1997;47:439–446.
67. Rodriguez-Arnao J, Jabbar A, Fulcher K, et al. Effects of growth hormone replacement on physical performance and body composition in GH deficient adults. *Clin Endocrinol* 1999;51:53–60.
68. Giannoulis MG, Martin FC, Nair KS, et al. Hormone replacement therapy and physical function in healthy older men. Time to talk hormones? *Endocrine Rev* 2012;33:314–377.
69. Sanada K, Miyachi M, Tanimoto M, et al. A cross-sectional study of sarcopenia in Japanese men and women: Reference values and association with cardiovascular risk factors. *Eur J Appl Physiol* 2010;110:57–65.
70. Kim TN, Yang SJ, Yoo HJ, et al. Prevalence of sarcopenia and sarcopenic obesity in Korean adults: The Korean sarcopenic obesity study. *Int J Obes (Lond)* 2009;33:885–892.
71. Hwang B, Lim JY, Lee J, et al. Prevalence rate and associated factors of sarcopenic obesity in Korean elderly population. *J Korean Med Sci* 2012;27:748–755.
72. Pongchaiyakul C, Limpawattana P, Kotruchin P, Rajatanavin R. Prevalence of sarcopenia and associated factors among Thai population. *J Bone Miner Metab* 2013;31:346–350.
73. Manini TM, Visser M, Won-Park S, et al. Knee extension strength cutpoints for maintaining mobility. *J Am Geriatr Soc* 2007;55:451–457.
74. Kim KE, Jang SN, Lim S, et al. Relationship between muscle mass and physical performance: Is it the same in older adults with weak muscle strength? *Age Ageing* 2012;41:799–803.



## EDITORIAL

## Growing research on sarcopenia in Asia

We, the Guest Editors of this special issue, are proud to publish 16 articles on sarcopenia from six Asian countries, including seven articles from Japan, four from Taiwan, two from Hong Kong, and one each from Korea, China, and Thailand. We searched PubMed using the key words “sarcopenia” and “human,” and found 97 original articles that were published in English in 2013 (from January to November). Among the articles, 17 were from Asian countries. Thus, researchers in Asian countries have contributed significantly to sarcopenia research.

Aging is an inevitable phenomenon, and the aging of skeletal muscle is no exception. It has been more than 20 years since Rosenberg first coined the term “sarcopenia,”<sup>1</sup> indicating that age-related muscle decline is associated with poor health status and adverse health outcomes in older adults. Along with the tremendous increase in the older population in Asia, sarcopenia has exerted a great impact on Asian populations. However, until recently, Asian researchers have not given great attention to sarcopenia research. Additionally, factors such as population aging, economic development and ethnic background vary extensively in Asian countries. Therefore, sarcopenia experts and researchers from China, Hong Kong, Japan, Korea, Malaysia, Taiwan, and Thailand organized the Asian Working Group for Sarcopenia (AWGS). Since March 2013, this working group has held several meetings in Taipei, Seoul and Kyoto to promote further sarcopenia research development in Asia. The AWGS also aims to focus on the epidemiology of sarcopenia in Asian countries, and has proposed a diagnostic algorithm based on currently available evidence in Asia. As a result of the efforts of AWGS, we are happy to announce that our consensus paper on the diagnostic algorithm and a systematic review of Asian evidence was published in the *Journal of the American Medical Directors Association*.<sup>2</sup> We hope that all of the articles in this special issue and the consensus paper will further inspire sarcopenia research in Asia.

In terms of the definition of sarcopenia, the European Working Group on Sarcopenia in Older People (EWGSOP) proposed an operational definition and diagnostic strategy that have become the most widely used in the world.<sup>3</sup> The EWGSOP definition requires measurements of muscle mass, muscle strength and/or physical performance for the diagnosis of sarcopenia. Based on discussions at the AWGS meetings, we

decided to take similar approaches to sarcopenia diagnosis. However, unlike the EWGSOP definition, we recommend measuring both muscle strength (grip strength) and physical performance (usual gait speed) as the initial screening test. For the usual gait speed, we recommend using 6-m usual gait speed without deceleration. Although the cut-offs of these measurements in Asians might differ from those in Caucasians because of variations in ethnicities, body size, lifestyles and cultural backgrounds, we utilize the EWGSOP definition of slow gait speed (0.8 m/s or less) due to a lack of outcome-based evidence. However, if we use the lowest 20th percentile of gait speed in community settings, according to most Asian studies, the cut-off would be higher than 1 m/s. Meanwhile, we have more data on the cut-offs of grip strength and muscle mass in Asian populations. Based on several epidemiological studies in Asia, we define low grip strength as <26 kg for men and <18 kg for women. The AWGS recommends using height-adjusted skeletal muscle mass, with the suggested cut-off values of 7.0 kg/m<sup>2</sup> in men and 5.4 kg/m<sup>2</sup> in women using dual X-ray absorptiometry (DXA). The suggested cut-off values are 7.0 kg/m<sup>2</sup> in men and 5.7 kg/m<sup>2</sup> in women when bioelectrical impedance analysis (BIA) is used. However, we should keep in mind that DXA and BIA are not yet available in many Asian countries for the screening of muscle mass. Therefore, we must develop an inexpensive measurement for assessing muscle mass.

In this special issue, to maintain consistency, we referred to “sarcopenia” only if authors measured gait speed, grip strength (quadriceps strength was acceptable) and muscle mass. Therefore, “low muscle mass” was used when authors only measured muscle mass. Additionally, many articles used different cut-off values for the grip strength and muscle mass measurements. Table 1 summarizes these data and the prevalence of sarcopenia. We also compared the difference in the diagnostic flow of sarcopenia across the AWGS, EWGSOP and International Working Group on Sarcopenia (IWGS), as shown in Table 2.

As described in the articles of this special issue, sarcopenia has a substantial impact on the health care of older adults. Therefore, additional research is required to further develop the diagnosis and treatment of sarcopenia. We hope that this special issue will inspire more Asian researchers to carry out sarcopenia research.

**Table 1** Surrogates comparison for Asian consensus

1 <sup>st</sup> Author and nationality	Available measurements	Cut-off definition	Cut-off values	Prevalence of sarcopenia	Research population	Reference population	Ref. no.
Assantachai Thailand	<ul style="list-style-type: none"> <li>• QS measured by a hand-held dynamometer: Lafayette Manual Muscle Test System (MMT)® model 01163 (Lafayette Instrument, Lafayette, IN, USA)</li> <li>• Total lean body mass, using BIA Model 450 (Biodynamics Corp. Seattle, WA, USA)</li> <li>• Timed 5-step test</li> <li>• Timed 5-chair stand test</li> <li>• 6-min walk test</li> </ul>	-	<b>QS</b> 18 kg in men 16 kg in women	Low QS: 32.9%	<i>n</i> = 950, aged ≥60 years	-	4
Wu Taiwan	<ul style="list-style-type: none"> <li>• Body composition by BIA (Tanita BC-418, Tanita Corp., Tokyo, Japan)</li> <li>• GS</li> <li>• Handgrip strength</li> </ul>	<b>ASM/ht<sup>2</sup>:</b> ① mean - 2SD of young adults ② 1 <sup>st</sup> quintile of study population <b>GS:</b> Sex- and height- specific 1 <sup>st</sup> quintile <b>Handgrip strength:</b> Sex- and BMI-specific 1 <sup>st</sup> quintile	① 6.76 kg/m <sup>2</sup> for men; 5.28 kg/m <sup>2</sup> for women ② 7.09 kg/m <sup>2</sup> for men; 5.70 kg/m <sup>2</sup> for women <b>GS:</b> Men: height ≤163 cm, 0.67 m/s, height >163 cm, 0.71 m/s Women: height ≤152 cm, 0.57 m/s, height >152 cm, 0.67 m/s <b>Handgrip strength</b> Men: BMI <22.1 kg/m <sup>2</sup> , 25.0 kg, BMI 22.1–24.3 kg/m <sup>2</sup> , 26.5 kg, BMI 24.4–26.3 kg/m <sup>2</sup> , 26.4 kg, BMI >26.3 kg/m <sup>2</sup> , 27.2 kg Women: BMI <22.3 kg/m <sup>2</sup> , 14.6 kg, BMI 22.3–24.2 kg/m <sup>2</sup> , 16.1 kg, BMI 24.3–26.8 kg/m <sup>2</sup> , 16.5 kg, BMI >26.8 kg/m <sup>2</sup> , 16.4 kg	① Using young ref. 5.4% in men 2.5% in women ② Using study ref. 8.2% in men 6.5% in women	2867 community-dwelling older adults Mean age: 74 ± 6.0 years, 50% women	998 healthy adults aged 20–40 years	5
Hsu Taiwan	<ul style="list-style-type: none"> <li>• Muscle mass by BIA (InBody 220, Seoul, South Korea)</li> <li>• GS: A 6-m walk</li> <li>• Handgrip strength by using a digital dynamometer (TTM-YD, Tokyo, Japan; 3 trials for each hand, using the best reading)</li> </ul>	<b>FFM/m<sup>2</sup>:</b> mean - 2SD of young adults <sup>6</sup> <b>GS:</b> EWGSOP cut-off <b>Handgrip strength:</b> <sup>7</sup>	<b>Muscle mass index:</b> 8.87 kg/m <sup>2</sup> in men 6.42 kg/m <sup>2</sup> in women <b>GS:</b> ≤0.8 m/s <b>Handgrip strength:</b> 22.5 kg	30.9% (109/353)	353 men living in facilities aged ≥65 years Mean age: 82.7 ± 5.3 years	-	8
Meng and Hu China	<ul style="list-style-type: none"> <li>• Muscle mass by DXA (GE Lunar)</li> <li>RASM: ASM/ht<sup>2</sup></li> <li>SMI%: ASM/weight × 100</li> <li>• Handgrip strength by a dynamometer (Jamar Plus+ digital hand dynamometer, USA; 1 trial for each hand, using the best reading)</li> <li>• GS: 6-m walk</li> </ul>	<b>RASM:</b> mean - 2SD of young adults <b>Handgrip strength:</b> <sup>7</sup> <b>GS:</b> EWGSOP cut-off	6.85 kg/m <sup>2</sup> by RASM, 28.0% by SMI% <b>Handgrip strength:</b> 22.4 kg <b>GS:</b> ≤0.8 m/s	Sarcopenia, 45.7%, Sarcopenic obesity, 4.9% by RASM Sarcopenia, 53.2%, Sarcopenic obesity, 11.5% by SMI%	Community-dwelling men aged ≥80 years, <i>n</i> = 101, mean age 88.8 ± 3.7 years	75 healthy young volunteers (male) aged 20–40 years	9

Liu Taiwan	<ul style="list-style-type: none"> <li>• Muscle mass by DXA (GE Healthcare, Madison, WI, USA)</li> <li>• Handgrip strength by a dynamometer (Smedley's Dynamo Meter; TTM, Tokyo, Japan; 3 trials for the dominant hand, using the highest reading)</li> <li>• GS: 6-m walk</li> </ul>	<p>ASM/ht<sup>2</sup>: 1st quintile of study population</p> <p>Handgrip strength &amp; GS: 1st quintile of study population</p>	<p><b>Muscle mass index:</b> 7.0 kg/m<sup>2</sup> in men, 5.9 kg/m<sup>2</sup> in women</p> <p><b>Handgrip strength:</b> 25 kg in men, 16 kg in women</p> <p><b>GS:</b> 1.0 m/s in men, 0.9 m/s in women</p>	9.4% in men, 9.8% in women	481 aged ≥65 years, male 55.5%	–	10
Wu Taiwan	<ul style="list-style-type: none"> <li>• Muscle mass by BIA (Tanita BC-418; Tanita, Tokyo, Japan)</li> <li>• Handgrip strength (Grip-D, TKK 5401, Japan; 2 trials for both hands, using the highest reading)</li> <li>• GS: 15-ft walking test</li> </ul>	<p><b>Total muscle mass/ ht<sup>2</sup>:</b> mean – 2SD of young adults<sup>8</sup></p> <p><b>Handgrip strength:</b> EWGSOP cut-off</p> <p><b>GS:</b> EWGSOP cut-off</p>	<p><b>Muscle mass index:</b> 7.70 kg/m<sup>2</sup> in men, 5.67 kg/m<sup>2</sup> in women</p> <p><b>Handgrip strength:</b> Men: BMI ≤24 kg/m<sup>2</sup>, 24.1–28 kg/m<sup>2</sup> and &gt;28 kg/m<sup>2</sup> were ≤29 kg, ≤30 kg and ≤32 kg Women: BMI ≤23 kg/m<sup>2</sup>, 23.1–26 kg/m<sup>2</sup>, 26.1–29 kg/m<sup>2</sup> and &gt;29 kg/m<sup>2</sup> were ≤17 kg, ≤17.3 kg, ≤18 kg and ≤21 kg <b>GS:</b> ≤0.8 m/sec</p>	Sarcopenia, 7.1%, Severe sarcopenia, 5.6%	Total 549 study subjects, 285 male and 264 female aged ≥ 65 years Mean age: 76.0 ± 6.2 years	–	11
Kim Korea	<ul style="list-style-type: none"> <li>• Muscle mass by DXA (Discovery-W, Hologic, Bedford, MA)</li> </ul>	<p><b>Muscle indices:</b> ASM/ht<sup>2</sup> and ASM/Wt: mean – 2SD of young adults or &lt;1<sup>st</sup> quintile of total body skeletal muscle mass/weight (TSM/Wt) from control subjects</p>	<p><b>ASM/ht<sup>2</sup>:</b> 7.40 kg/m<sup>2</sup> in men, 5.14 kg/m<sup>2</sup> in women</p> <p><b>ASM/Wt:</b> 29.5% in men, 23.2% in women</p> <p><b>TSM/Wt:</b> 34.9% in men, 25.8% in women</p>	–	414 adults aged ≥65 years Mean age: men 70.6 years and women 70.9 years	<p><b>ASM/ht<sup>2</sup>:</b> young healthy volunteers, aged 20–40, <i>n</i> = 145 (54 men, 91 women)</p> <p><b>ASM/Wt:</b> 2392 healthy adults aged 20–40 years (1054 men, 1338 women)</p>	12
Ishii Japan	<ul style="list-style-type: none"> <li>• Muscle mass by BIA (Inbody 430, Biospace, Seoul, Korea)</li> <li>• Handgrip strength by a grip strength dynamometer (Takei Scientific Instruments, Niigata, Japan)[2 trials for dominant hand, using the higher reading]</li> <li>• GS: middle 5 m over an 11-m straight course at their usual speed</li> </ul>	<p>ASM/ht<sup>2</sup>: mean – 2SD of young adults<sup>13</sup></p> <p>Handgrip strength: 1<sup>st</sup> quintile of study population</p> <p>GS: 1<sup>st</sup> quintile of study population</p>	<p><b>Muscle mass index:</b> &lt;7.0 kg/m<sup>2</sup> in men, &lt;5.8 kg/m<sup>2</sup> in women</p> <p><b>Handgrip strength:</b> 30 kg in men, 20 kg in women</p> <p><b>GS:</b> ≤1.26 m/s</p>	14.2% in men, 22.1% in women	1971 functionally independent, community-dwelling adults aged ≥65 years 977 men, 994 women	–	14
Sampaio Japan	<ul style="list-style-type: none"> <li>• Muscle mass by BIA (Inbody 430; Biospace, Seoul, Korea)</li> <li>• Handgrip strength using a dynamometer (Smedley's Dynamo Meter, TTM, Tokyo, Japan; 1 trial for each hand, using the higher reading)</li> <li>• GS: 10-m walking in a 12-m length</li> </ul>	<p><b>Total muscle mass/ht<sup>2</sup>:</b> 1<sup>st</sup> quintile of study population</p>	<p><b>Total muscle mass/ht<sup>2</sup>:</b> 8.81 kg/m<sup>2</sup> in men, 7.57 kg/m<sup>2</sup> in women</p>	–	Community-dwelling Japanese older adults ( <i>n</i> = 175; male = 84, female = 91)	–	15

Table 1 Continued

1 <sup>st</sup> Author and nationality	Available measurements	Cut-off definition	Cut-off values	Prevalence of sarcopenia	Research population	Reference population	Ref. no.
Shimokata, Japan	<ul style="list-style-type: none"> <li>• Muscle mass by DXA (QDR-4500; Hologic, Bedford, MA, USA)</li> <li>• Leg extension power measured using the T.K.K.4236 adjustable seat and foot plate (Takei, Niigata, Japan; the maximum values of 8 tests were analyzed)</li> <li>• Grip strength was measured using the T.K.K.4301 (Takei; maximum values of 2 tests for dominant hand were analyzed)</li> </ul>	ASM/ht <sup>2</sup> : mean – 2SD of young adults <sup>16</sup>	ASM/ht <sup>2</sup> : <6.87 kg/m <sup>2</sup> in men <5.46 kg/m <sup>2</sup> in women	The prevalence of low muscle mass: 27.1% in men 16.4% in women	NILS-LSA 1090 men, mean age 59.3 ± 11.0 years 1081 women, mean age 59.3 ± 10.9 years	–	17
Yamada Japan	<ul style="list-style-type: none"> <li>• Muscle mass by BIA (Inbody 720; Biospace, Seoul, Korea)</li> </ul>	ASM/ht <sup>2</sup> : 1 <sup>st</sup> quintile of study population	ASM/ht <sup>2</sup> <b>For men</b> 65–69; 7.06 kg/m <sup>2</sup> 70–74; 7.09 kg/m <sup>2</sup> 75–79; 6.83 kg/m <sup>2</sup> 65–79; 7.02 kg/m <sup>2</sup> <b>For women</b> 65–69; 5.61 kg/m <sup>2</sup> 70–74; 5.63 kg/m <sup>2</sup> 75–79; 5.54 kg/m <sup>2</sup> 65–79; 5.61 kg/m <sup>2</sup>	–	Community healthy men (n = 16 379) and women (n = 21 660) aged 40–79 years Mean age: 54.5 ± 9.9 years, 56.9% women	–	18
Yoshida Japan	<ul style="list-style-type: none"> <li>• Muscle mass by BIA (MC-980A; Tanita, Tokyo, Japan)</li> <li>• Handgrip strength by a hand dynamometer Grip-D (Takei; 1 trial for the dominant hand)</li> <li>• GS: middle 2.4 m in a 6.4 m walking at their usual pace for five times, using the average value</li> </ul>	ASM/ht <sup>2</sup> and Handgrip strength: sex-specific 1st quintile of study population GS: EWGSOP cut-off	ASM/ht <sup>2</sup> : 7.09 kg/m <sup>2</sup> in men, 5.91 kg/m <sup>2</sup> in women Handgrip strength: 28.8 kg in men, 18.2 kg in women GS: ≤0.8 m/s	age ≥65 years: 8.2% in men and 6.8% in women) age ≥80 years: 25.0% in men and 12.2% in women	4811 people aged 65 years and over, 48.7% men: (n = 2343, mean age 72.2 ± 5.5 years) women: (n = 2468, mean age 72.1 ± 5.7 years)	–	19
Yu Hong Kong	<ul style="list-style-type: none"> <li>• Muscle mass by DXA (Hologic Delphi W4500 densitometer; Hologic, Bedford, MA, USA)</li> <li>• Grip strength using a dynamometer (JAMAR Hand Dynamometer 5030J0; 2 trials for each hand, using the average value between right and left hand)</li> <li>• Walking speed: a 6-m walking speed (2 trials, using best time recorded)</li> </ul>	ASM/ht <sup>2</sup> : 1st quintile of study population Handgrip strength: 1st quintile of study population GS: EWGSOP cut-off	ASM/ht <sup>2</sup> <6.52 kg/m <sup>2</sup> in males <5.44 kg/m <sup>2</sup> in females Handgrip strength: ≤28 kg in males ≤18 kg in females GS ≤0.8 m/s	361 (9.0%)	4000 community-dwelling men and women aged 65 years and above, men 50% Mean age: 72.5 ± 5.2 years	–	20

ASM, appendicular skeletal mass; BIA, bioelectrical impedance analysis; BMI, body mass index; DXA, dual X-ray absorptiometry; EWGSOP, European Working Group on Sarcopenia in Older People; FFM, fat free mass; GS, gait speed; QS, quadriceps strength; RASM, relative appendicular skeletal muscle mass; SMI, skeletal muscle index.

**Table 2** Comparison of diagnostic algorithm of sarcopenia among Asian Working Group for Sarcopenia, European Working Group on Sarcopenia in Older People, and International Working Group on Sarcopenia

	AWGS	EWGSOP	IWGS
Target for screening	Community-dwelling older adults and older people with certain clinical conditions, such as presence of recent functional decline or functional impairment, unintentional body weight loss for over 5% in a month, depressive mood or cognitive impairment, repeated falls, malnutrition, chronic conditions, such as chronic heart failure, chronic obstructive lung disease, diabetes mellitus, chronic kidney disease, connective tissue disease, tuberculosis infection, and other chronic wasting conditions	Community-dwelling people aged $\geq 65$ years	Individuals with functional decline, mobility-related difficulties, history of recurrent falls, recent unintentional body weight loss, post-hospitalization, and chronic conditions, such as type 2 diabetes, congestive heart failure, chronic kidney disease, chronic obstructive lung disease, rheumatoid arthritis, and cancer
Target age group	$\geq 60$ years or $\geq 65$ years depending on the definition of older adults in each country	$\geq 65$ years	Not specified
Screening	Gait speed and handgrip strength	Gait speed	Gait speed
Cut-off of gait speed	0.8 m/s	0.8 m/s	1.0 m/s
Cut-off of handgrip strength	26 kg in men and 18 kg in women	30 kg in men and 20 kg in women	NA
Cut-off of muscle mass (appendicular muscle mass/ht <sup>2</sup> )	7.0 kg/m <sup>2</sup> in men and 5.4 kg/m <sup>2</sup> in women by DXA, 7.0 kg/m <sup>2</sup> in men and 5.7 kg/m <sup>2</sup> in women by BIA	Mean - 2SD of young adults	7.23 kg/m <sup>2</sup> in men and 5.67 kg/m <sup>2</sup> in women

AWGS, Asian Working Group for Sarcopenia; BIA, bioelectrical impedance analysis; BMI, body mass index; DXA, dual X-ray absorptiometry; EWGSOP, European Working Group on Sarcopenia in Older People; IWGS, International Working Group on Sarcopenia.

## Acknowledgments

We thank the National Center for Geriatrics and Gerontology for their kind support of this special issue publication. We also express sincere thanks for all the members of AWGS. The names and affiliations of all the members are listed below.

Masahiro Akishita, Department of Geriatric Medicine, The University of Tokyo, Tokyo, Japan

Prasert Assantachai, Department of Preventive and Social Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand

Hidenori Arai, Department of Human Health Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan

Tung-Wai Auyeung, The S H Ho Centre for Gerontology and Geriatrics, The Chinese University of Hong Kong, Hong Kong, China

Kamaruzzaman Shahrul Bahyah, Department of Medicine, University of Malaya, Kuala Lumpur, Malaysia

Ming-Yueh Chou, Geriatric Medicine Center, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan

Liang-Kung Chen, Center for Geriatrics and Gerontology, Taipei Veterans General Hospital, Taipei, Taiwan

Liang-Yu Chen, Center for Geriatrics and Gerontology, Taipei Veterans General Hospital, Taipei, Taiwan

Pi-Shan Hsu, Department of Family Medicine, Taichung Hospital, Ministry of Health and Welfare, Taichung, Taiwan

Orapitchaya Krairit, Department of Internal Medicine, Ramathibodi Hospital, Mahidol University, Thailand

Jenny SW Lee, The S H Ho Centre for Gerontology and Geriatrics, The Chinese University of Hong Kong, Hong Kong, China

Wei-Ju Lee, Department of Family Medicine, Taipei Veterans General Hospital Yuanshan Branch, I-Lan, Taiwan

Yunhwan Lee, Department of Preventive Medicine and Public Health, Ajou University School of Medicine, Suwon, South Korea

Chih-Kuang Liang, Geriatric Medicine Center, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan

Panita Limpawattana, Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand

Chu-Sheng Lin, Center for Geriatrics and Gerontology, Taichung Veterans General Hospital, Taichung, Taiwan

Li-Kuo Liu, Center for Geriatrics and Gerontology, Taipei Veterans General Hospital, Taipei, Taiwan

Li-Ning Peng, Center for Geriatrics and Gerontology, Taipei Veterans General Hospital, Taipei, Taiwan

Shosuke Satake, Department of Comprehensive Geriatric Medicine, National Center for Geriatrics and Gerontology, Obu, Japan

Takao Suzuki, Research Institute, National Center for Geriatrics and Gerontology, Obu, Japan

Chang Won Won, Department of Family Medicine, Kyung Hee University School of Medicine, Seoul, South Korea

Jean Woo, The S H Ho Centre for Gerontology and Geriatrics, The Chinese University of Hong Kong, Hong Kong, China

Chih-Hsing Wu, Department of Family Medicine, National Cheng Kung University Hospital and College of Medicine, Tainan, Taiwan

Si-Nan Wu, Beijing Institute of Geriatrics, Beijing Hospital, Ministry of Health, Beijing, China

Teimei Zhang, Beijing Institute of Geriatrics, Beijing Hospital, Ministry of Health, Beijing, China

Ping Zeng, Beijing Institute of Geriatrics, Beijing Hospital, Ministry of Health, Beijing, China

## Disclosure statement

The authors declare no conflict of interest.

Hidegori Arai,<sup>1</sup> Masahiro Akishita<sup>2</sup> and Liang-Kung Chen<sup>3</sup>

<sup>1</sup>Department of Human Health Sciences, Kyoto University Graduate School of Medicine, Kyoto, <sup>2</sup>Department of Geriatric Medicine, The University of Tokyo, Tokyo, Japan; and <sup>3</sup>Center for Geriatrics and Gerontology, Taipei Veterans General Hospital, Taipei, Taiwan

## References

1 Rosenberg IH. Summary comments. *Am J Clin Nutr* 1989; **50**: 1231S–1233S.

- 2 Chen LK, Liu LK, Woo J *et al*. Sarcopenia in Asia: consensus report of the Asian Working Group for Sarcopenia. *J Am Med Dir Assoc* (in press).
- 3 Cruz-Jentoft AJ, Baeyens JP, Bauer JM *et al*. Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in Older People. *Age Ageing* 2010; **39**: 412–423.
- 4 Assantachai P, Muangpaisan W, Intalapaporn S, Sittichai K, Udompunturak S. Cut-off points of quadriceps strength, declines and relationships of sarcopenia-related variables among Thai community-dwelling older people. *Geriatr Gerontol Int* 2014; **14** (Suppl. 1): 61–68.
- 5 Wu IC, Lin CC, Hsiung CA *et al*. Epidemiology of Sarcopenia among community-dwelling older adults in Taiwan: a pooled analysis for a broader adoption of sarcopenia assessments. *Geriatr Gerontol Int* 2014; **14** (Suppl. 1): 52–60.
- 6 Hsu YH, Liang CK, Chou MY *et al*. Association of cognitive impairment, depressive symptoms and sarcopenia among older healthy men in the veterans retirement community in southern Taiwan: a cross-sectional study. *Geriatr Gerontol Int* 2014; **14** (Suppl. 1): 102–108.
- 7 Liu LK, Lee WJ, Liu CL *et al*. Age-related skeletal muscle mass loss and physical performance in Taiwan: implications to diagnostic strategy of sarcopenia in Asia. *Geriatr Gerontol Int* 2013; **4**: 964–971.
- 8 Lee WJ, Liu LK, Peng LN, Lin MH, Chen LK, ILAS Research Group. Comparisons of sarcopenia defined by IWGS and EWGSOP criteria among older people: results from the I-Lan longitudinal aging study. *J Am Med Dir Assoc* 2013; **14** (7): 528.e1–528.e7.
- 9 Meng P, Hu YX, Fan L *et al*. Sarcopenia and sarcopenic obesity among men age 80 years and older in Beijing: prevalence and its association with functional performance. *Geriatr Gerontol Int* 2014; **14** (Suppl. 1): 29–35.
- 10 Liu LK, Lee WJ, Chen LY *et al*. Sarcopenia and its association with cardiometabolic and functional characteristics in Taiwan: results from I-Lan longitudinal aging study. *Geriatr Gerontol Int* 2014; **14** (Suppl. 1): 36–45.
- 11 Wu CH, Chen KT, Hou MT *et al*. Prevalence and associated risk factors of sarcopenia and severe sarcopenia in older Taiwanese living in rural community: The Tianliao Old People study 04. *Geriatr Gerontol Int* 2014; **14** (Suppl. 1): 69–75.
- 12 Kim KS, Park KS, Kim MJ, Kim SK, Cho YW, Park SW. Type 2 diabetes is associated with low muscle mass in older adults. *Geriatr Gerontol Int* 2014; **14** (Suppl. 1): 115–121.
- 13 Tanimoto Y, Watanabe M, Sun W *et al*. Association between muscle mass and disability in performing instrumental activities of daily living (IADL) in community-dwelling elderly in Japan. *Arch Gerontol Geriatr* 2012; **54**: e230–e233.
- 14 Ishii S, Tanaka T, Iijima K. Development of a simple screening test for sarcopenia in older adults. *Geriatr Gerontol Int* 2014; **14** (Suppl. 1): 93–101.
- 15 Sampaio RAC, Sampaio PYS, Yamada M *et al*. Arterial stiffness is associated with low skeletal muscle mass in Japanese community-dwelling older adults. *Geriatr Gerontol Int* 2014; **14** (Suppl. 1): 109–114.
- 16 Sanada K, Miyachi M, Tanimoto M *et al*. 2010. A cross-sectional study of sarcopenia in Japanese men and women: reference values and association with cardiovascular risk factors. *Eur J Appl Physiol* 2010; **110**: 57–65.
- 17 Shimokata H, Ando F, Yuki A, Otsuka R. Age-related changes in skeletal muscle mass among community-dwelling Japanese – a 12-year longitudinal study. *Geriatr Gerontol Int* 2014; **14** (Suppl. 1): 85–92.

- 18 Yamada M, Moriguchi Y, Mitani T, Aoyama T, Arai H. Age-dependent changes in skeletal muscle mass and visceral fat area in Japanese adults from 40–79 years of age. *Geriatr Gerontol Int* 2014; **14** (Suppl. 1): 8–14.
- 19 Yoshida D, Suzuki T, Shimada H *et al.* The prevalence of sarcopenia determined using two different algorithms. *Geriatr Gerontol Int* 2014; **14** (Suppl. 1): 46–51.
- 20 Yu R, Wong M, Leung J, Lee J, Auyeung TW, Woo J. Incidence, risk factors and the protective effect of high body mass index against sarcopenia in community-living older Chinese people. *Geriatr Gerontol Int* 2014; **14** (Suppl. 1): 15–28.



## ORIGINAL ARTICLE

# Age-dependent changes in skeletal muscle mass and visceral fat area in Japanese adults from 40 to 79 years-of-age

Minoru Yamada,<sup>1</sup> Yoko Moriguchi,<sup>2</sup> Takahiro Mitani,<sup>2</sup> Tomoki Aoyama<sup>1</sup> and Hidenori Arai<sup>1</sup>

<sup>1</sup>Department of Human Health Sciences, Kyoto University Graduate School of Medicine, Kyoto, and <sup>2</sup>OG Sports Co., Ltd, Osaka, Japan

**Aim:** The age-dependent loss of skeletal muscle mass is highly concerning in diverse aging populations. However, age-dependent changes in muscle mass and the visceral fat area have not been well documented in Asian populations. The aim of the present study was to evaluate the age-dependent changes in skeletal muscle mass and the visceral fat area in Japanese adults from 40 to 79 years-of-age.

**Methods:** This was a cross-sectional study. Healthy men ( $n = 16\,379$ ) and women ( $n = 21\,660$ ) aged 40–79 years participated in the present study. The skeletal muscle mass and visceral fat area were measured in the study participants by bioelectrical impedance. The muscle mass data were converted into the skeletal muscle mass index (SMI) by dividing the weight by the height squared ( $\text{kg}/\text{m}^2$ ).

**Results:** The SMI showed an age-dependent decrease in both sexes. Between 40 and 79 years, the total SMI decreased by 10.8% in men and by 6.4% in women. The arm SMI decreased by 12.6% in men and 4.1% in women, and the leg SMI decreased by 10.1% in men and by 7.1% in women in the same period. In contrast, the visceral fat area showed an age-dependent increase in both sexes. The visceral fat area increased by 42.9% in men and by 65.3% in women. The multiple regression analysis showed that the SMI was negatively associated with visceral obesity in both sexes.

**Conclusions:** In Japanese adults, sex-specific changes in skeletal muscle mass are more prominent in the arm than in the leg. Furthermore, the age-dependent increases in visceral adipose tissue might lead to loss of skeletal muscle mass. *Geriatr Gerontol Int* 2014; 14 (Suppl. 1): 8–14.

**Keywords:** age-dependent, Japanese, skeletal muscle mass, visceral fat area.

## Introduction

Sarcopenia is an age-dependent loss of skeletal muscle mass, and is a serious medical concern in older populations.<sup>1,2</sup> Sarcopenia is characterized by an impaired state of health associated with mobility disorders, an increased risk of falls and fractures, an impaired ability to carry out activities of daily living, disabilities, and a loss of independence.<sup>3–5</sup>

Previous epidemiological studies of sarcopenia in several countries have shown a disease prevalence of 5–40% in older men and 7–70% in older women.<sup>6–18</sup> In general, the prevalence of sarcopenia is approximately 25% in older men and 20% in older women. Notably,

previous work from this laboratory has shown that sarcopenia is highly prevalent among Japanese adults aged 80 years and older.<sup>18</sup> Because older adults have a greater potential for health problems than young adults, it is very important to begin prevention of sarcopenia early, possibly before the age of 65 years. Two previous studies from the USA and Europe have shown that the age-dependent loss of skeletal muscle mass starts at approximately 50 years-of-age, and that skeletal muscle mass declines by 6.6–23.3% until 79 years-of-age.<sup>19,20</sup> However, age-dependent changes in muscle mass in Asians are not well documented.

Visceral adiposity, which is the basis of metabolic syndrome and cardiovascular disease, is aggravated with age.<sup>21</sup> The visceral adipose tissue produces many inflammatory cytokines, such as tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ) and interleukin (IL)-6,<sup>22</sup> and expression of these inflammatory cytokines can lead to increased skeletal muscle breakdown.<sup>23</sup> Furthermore, previous studies have shown that increased visceral fat area is associated with decreased skeletal muscle mass in a

Accepted for publication November 10, 2013.

Correspondence: Dr Hidenori Arai MD PhD, Department of Human Health Sciences, Kyoto University Graduate School of Medicine, 53 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan. Email: harai@kuhp.kyoto-u.ac.jp

small sample of older adults.<sup>24</sup> However, the association of skeletal muscle mass with age-dependent changes in visceral fat in a large population has not previously been shown.

The primary aim of the present study was to evaluate the age-dependent changes in skeletal muscle mass and visceral fat area using a large cross-sectional cohort of Japanese adults between 40 and 79 years-of-age. We also evaluated sex differences in skeletal muscle loss in the arms and legs. The secondary aim of the present study was to evaluate the association between the skeletal muscle mass and visceral fat area.

## Methods

### Participants

Participants were recruited by advertisements at several fitness and community centers. The participants in the present study were limited to visitors to these centers in the Kyoto, Osaka, and Hyogo prefectures in Japan. The inclusion criteria were an age of 40–79 years, living in the community and the ability to walk independently (including with a cane). The exclusion criteria were a certification of frailty status by the long-term care insurance service in Japan and artificial implants, such as cardiac pacemakers and replacement joints, which would interfere with accurate bioimpedance measurements. An interview was also used to identify those with the following exclusion criteria: severe cognitive impairment; severe cardiac, pulmonary, or musculoskeletal disorders; and comorbidities associated with greater risk of falls, such as Parkinson's disease or stroke. Because the purpose of the present study was to address physiological age-dependent changes in body composition, we excluded frail elderly and adults with those comorbidities. The present study was carried out in accordance with the guidelines of the Declaration of Helsinki, and the study protocol was reviewed and approved by the Ethics Committee of the Kyoto University Graduate School of Medicine.

Healthy men ( $n = 16\,379$ ) and women ( $n = 21\,660$ ) aged 40–79 years participated in the present study. The male participants were divided into eight groups according to age: 40–44 ( $n = 3697$ ), 45–49 ( $n = 3151$ ), 50–54 ( $n = 2202$ ), 55–59 ( $n = 1952$ ), 60–64 ( $n = 2274$ ), 65–69 ( $n = 1683$ ), 70–74 ( $n = 1030$ ), and 75–79 ( $n = 390$ ) years. The female participants were similarly divided into eight groups according to age: 40–44 ( $n = 3828$ ), 45–49 ( $n = 3686$ ), 50–54 ( $n = 3597$ ), 55–59 ( $n = 3002$ ), 60–64 ( $n = 3490$ ), 65–69 ( $n = 2314$ ), 70–74 ( $n = 1269$ ), and 75–79 ( $n = 474$ ) years.

### Skeletal muscle mass index and visceral fat area

A bioelectrical impedance data acquisition system (Inbody 720; Biospace, Seoul, Korea) was used to deter-

mine bioelectrical impedance.<sup>25</sup> This system uses an electrical current at different frequencies (5, 50, 250, 500, and 1000 kHz) to directly measure the amount of extracellular and intracellular water in the body. The study participants stood on two metallic electrodes and held metallic grip electrodes. Using segmental body composition and muscle mass, a value for the appendicular skeletal muscle mass was determined and used for further analysis. The muscle mass was converted into the skeletal muscle mass index (SMI) by dividing the weight by the height squared ( $\text{kg}/\text{m}^2$ ). This index has been used in several epidemiological studies.<sup>6,26</sup> Additionally, the SMI of the arms and legs was calculated. The visceral fat area was determined by evaluating a transverse cross-section of the fourth and fifth abdominal lumbar area.

### Statistical analysis

Differences in the total SMI, arm SMI, leg SMI, and visceral fat area among the eight age groups were examined using an analysis of variance. Multiple regression models were applied to determine the relationship between the visceral fat area and the SMI, adjusted for age and weight in each sex. The data were managed and analyzed using SPSS (Windows version 18.0; SPSS, Chicago, IL, USA). A  $P$ -value of  $<0.05$  was considered to show statistical significance for all analyses.

## Results

The mean age of the study participants was  $54.5 \pm 9.9$  years, and 21 660 (56.9%) of the participants were women. The total SMI showed an age-dependent decrease in both sexes (men,  $F = 251.1$ ,  $P < 0.001$ ; women,  $F = 135.6$ ,  $P < 0.001$ ; Table 1). The percentage change in the total SMI at 40–44 years showed an age-dependent decrease in both sexes (Fig. 1, Table 1). In those aged over 65 years, the percentage change in the total SMI was greater in men than in women. In addition, the 20th percentile of total SMI in men and women aged 65–79 years was  $7.02 \text{ kg}/\text{m}^2$  and  $5.61 \text{ kg}/\text{m}^2$ , respectively (Table 2).

To compare the age-dependent changes in muscle mass in the upper and lower limbs in this cohort, we analyzed the arm and leg SMI. The arm SMI showed an age-dependent decrease in both sexes (men,  $F = 132.1$ ,  $P < 0.001$ ; women,  $F = 24.1$ ,  $P < 0.001$ ; Table 1). The percentage change in the arm SMI using the 40–44 years group as a reference also showed an age-dependent decrease in both sexes (Fig. 2, Table 1).


Similarly to the arm SMI, the leg SMI also showed an age-dependent decrease in both sexes (men,  $F = 273.2$ ,  $P < 0.001$ ; women,  $F = 192.2$ ,  $P < 0.001$ ; Table 1). The percentage change in the leg SMI also showed an

**Table 1** Participant characteristics by age half decade

		Overall			40–44 years			45–49 years			50–54 years			55–59		
		Men ( <i>n</i> = 16 379)			Men ( <i>n</i> = 3697)			Men ( <i>n</i> = 3151)			Men ( <i>n</i> = 2202)			Men ( <i>n</i> = 1952)		
		Women ( <i>n</i> = 21 660)			Women ( <i>n</i> = 3828)			Women ( <i>n</i> = 3686)			Women ( <i>n</i> = 3597)			Women ( <i>n</i> = 3002)		
		Mean	SD	% change over 40–44 years	Mean	SD	% change over 40–44 years	Mean	SD	% change over 40–44 years	Mean	SD	% change over 40–44 years	Mean	SD	% change over 40–44 years
Total SMI (kg/m <sup>2</sup> )	Men	7.97	0.73	–	8.20	0.78	–	8.11	0.66	–1.0	8.11	0.67	–1.1	7.98	0.64	–2.7
	Women	6.26	0.64	–	6.41	0.67	–	6.39	0.64	–0.3	6.33	0.64	–1.3	6.23	0.59	–2.8
Arm SMI (kg/m <sup>2</sup> )	Men	2.08	0.28	–	2.14	0.31	–	2.11	0.26	–1.4	2.11	0.26	–1.2	2.08	0.24	–3.0
	Women	1.47	0.22	–	1.49	0.24	–	1.49	0.23	–0.5	1.47	0.22	–1.4	1.46	0.21	–2.3
Leg SMI (kg/m <sup>2</sup> )	Men	7.98	0.73	–	6.06	0.51	–	6.00	0.46	–0.9	5.99	0.46	–1.1	5.91	0.45	–2.5
	Women	6.26	0.64	–	4.92	0.48	–	4.91	0.45	–0.3	4.85	0.46	–1.3	4.77	0.42	–3.0
Visceral fat area (cm <sup>2</sup> )	Men	100.6	29.2	–	88.4	28.8	–	91.9	27.1	4.0	98.9	28.8	11.9	103.5	25.7	17.1
	Women	84.7	27.4	–	68.0	25.3	–	72.1	23.9	6.0	79.3	23.6	16.5	89.4	23.0	31.5
		60–64 years			65–69 years			70–74 years			75–79 years			ANOVA		
		Men ( <i>n</i> = 2274)			Men ( <i>n</i> = 1683)			Men ( <i>n</i> = 1030)			Men ( <i>n</i> = 390)					
		Women ( <i>n</i> = 3490)			Women ( <i>n</i> = 2314)			Women ( <i>n</i> = 1269)			Women ( <i>n</i> = 474)					
		Mean	SD	% change over 40–44 years	Mean	SD	% change over 40–44 years	Mean	SD	% change over 40–44 years	Mean	SD	% change over 40–44 years	<i>F</i> -value	<i>P</i> -value	
Total SMI (kg/m <sup>2</sup> )	Men	7.84	0.68	–4.3	7.64	0.67	–6.9	7.59	0.66	–7.4	7.32	0.62	–10.8	251.1	<0.001	
	Women	6.14	0.61	–4.2	6.08	0.60	–5.2	6.09	0.55	–5.1	6.00	0.60	–6.4	135.6	<0.001	
Arm SMI (kg/m <sup>2</sup> )	Men	2.05	0.25	–4.4	1.99	0.25	–6.9	1.96	0.24	–8.5	1.87	0.26	–12.6	132.1	<0.001	
	Women	1.45	0.22	–3.1	1.44	0.21	–3.6	1.46	0.20	–2.5	1.43	0.21	–4.1	24.1	<0.001	
Leg SMI (kg/m <sup>2</sup> )	Men	5.80	0.48	–4.3	5.64	0.46	–6.9	5.64	0.51	–7.0	5.45	0.45	–10.1	273.2	<0.001	
	Women	4.69	0.43	–4.6	4.64	0.44	–5.7	4.63	0.41	–5.9	4.57	0.45	–7.1	192.2	<0.001	
Visceral fat area (cm <sup>2</sup> )	Men	108.3	26.2	22.5	113.0	25.7	27.8	122.3	25.1	38.3	126.4	25.2	42.9	376.9	<0.001	
	Women	94.0	23.3	38.2	101.6	23.0	49.4	108.5	24.1	59.5	112.4	29.3	65.3	966.7	<0.001	

Percentage change of 40–44 years = (absolute change value / 40–44 years value) × 100. SMI, skeletal muscle mass index.

## Age-dependent decreases in skeletal muscle mass



**Figure 1** The percentage of change in the total skeletal muscle mass index in each sex and each age group, using 40–44 years-of-age as a reference.

**Table 2** 20th percentile of total skeletal muscle mass index ( $\text{kg}/\text{m}^2$ ) in both sexes

Age group (years)	20th percentile of SMI	
	Men	Women
65–69	7.06	5.61
70–74	7.09	5.63
75–79	6.83	5.54
65–79	7.02	5.61

SMI, skeletal muscle mass index.



age-dependent decrease in both sexes (Fig. 2, Table 1). The age-dependent changes in the leg SMI were similar in men and women. However, the age-dependent changes in the arm SMI were greater in men than in women.

Next, we examined the age-dependent changes in visceral obesity. The visceral fat area showed an age-dependent increase in both sexes (men,  $F = 376.9$ ,  $P < 0.001$ ; women,  $F = 966.7$ ,  $P < 0.001$ ; Table 1). The percentage change from 40–44 years in the visceral fat area showed an age-dependent increase in both sexes (Fig. 3, Table 1).

To examine the association between skeletal muscle mass and visceral obesity, we carried out a multiple regression analysis using the SMI as an outcome. We found that the visceral fat area, age, and weight were significant and independent determinants of the SMI in both men ( $\beta = -0.586$ ) and women ( $\beta = -0.627$ ; Table 3). Therefore, the age-dependent change in the SMI was negatively associated with the visceral-fat area in both sexes.

## Discussion

The current cross-sectional study was carried out to evaluate the SMI in Japanese adults aged between 40




**Figure 2** The percentage of change in the (a) arm and (b) leg skeletal muscle mass index (SMI) in each sex and each age group using 40–44 years-of-age as a reference.

and 79 years. Our data show that the SMI decreased age-dependently in both sexes. Notably, regarding the age-dependent decreases in the total SMI and in those aged over 65 years, the percentage change in the total SMI was greater in men than in women. From 40 to 79 years, the total SMI decreased by 10.8% in men and by 6.4% in women. Previous epidemiological studies of body composition have shown that between 40 and 79 years, the fat-free mass decreases by 6.6–23.3% in both sexes.<sup>19,20</sup> The age-dependent increases in inflammatory cytokines, such as IL-6 and TNF- $\alpha$ , can result in increased skeletal muscle breakdown.<sup>23</sup> In contrast, the age-dependent decrease in anabolic hormones, such as testosterone, growth hormone, and insulin-like growth factor-1 (IGF-1), might lead to a loss of skeletal muscle

mass.<sup>27,28</sup> In addition, there is also an age-dependent decrease in the amount of physical activity and energy intake. These behavioral changes can enhance the age-dependent reduction in skeletal muscle mass.

Interestingly, in those aged over 65 years, age-dependent decreases in total SMI were greater in men than in women. Furthermore, this age-dependent sex difference was more prominent in the arm than in the leg. From 40 to 79 years, the arm SMI decreased by 12.6% in men and by 4.1% in women. This is consistent to the previous studies in Japanese older adults. Kitamura *et al.* reported that the arm lean tissue mass was  $5.97 \pm 0.75$  and  $5.01 \pm 0.67$  in men, and  $3.56 \pm 0.54$  and  $3.24$  in women aged in their 40s and 70s, respectively.<sup>29</sup> Based on their data, the percentage change in the arm lean tissue mass in men is  $-16.0\%$  and is  $-8.9\%$  in women. However, there is no sex difference in the percentage change in the leg lean tissue mass. The mechanism of this sex difference in the arm and leg lean tissue mass change is not clear. In general, older Japanese women frequently use the upper limbs, such as when washing and cooking. However, older Japanese men usually do not carry out such work. Therefore, it is



**Figure 3** The percentage of change in the visceral fat area in each sex and each age group using 40–44 years-of-age as a reference.

possible that these behavioral differences lead to greater age-dependent decreases in the arm SMI in men than in women. As another possibility, Baumgartner reported that the sex hormone signal is an important factor for muscle mass in men, but not in women; however, physical activity is an important factor for muscle mass in both sexes.<sup>30</sup> Furthermore, previous studies have shown that 20% of men older than 60 years, 30% of men older than 70 years, and 50% of men older than 80 years have serum testosterone levels below the normal range.<sup>31</sup> Thus, it is also possible that the sex hormone-dependent changes in muscle mass are greater in men than in women. Therefore, age-dependent gender differences in the SMI might be influenced by daily activity or alterations in sex hormone levels.

The present data show that aging is associated with a progressive increase in visceral fat area in both sexes. From 40 to 79 years of age, the visceral fat area increased by 42.9% in men and by 65.3% in women. Furthermore, the SMI was negatively associated with the visceral fat area when adjusted for age and body weight in both sexes. The visceral adipose tissue produces many catabolic factors, such as TNF- $\alpha$  and IL-6.<sup>22</sup> Therefore, the age-dependent increases in both visceral adipose tissue and inflammatory cytokines might lead to a loss of skeletal muscle mass. Recently, sarcopenic obesity has been defined as both low muscle mass and high adipose tissue in older adults, and the health-related risk is higher in sarcopenic obesity than in sarcopenia.<sup>32</sup> The current data show that the age-dependent changes in body composition can accelerate sarcopenic obesity. These results suggest that it is very important to begin prevention of sarcopenia and sarcopenic obesity as early as possible.

According to our analysis of this cohort, we found that the 20th percentile of total SMI in men and women aged 65–79 years was  $7.02 \text{ kg/m}^2$  and  $5.61 \text{ kg/m}^2$ , respectively. These values were slightly higher than those determined by the young adult mean in our database (men  $6.75 \text{ kg/m}^2$ ; women  $5.07 \text{ kg/m}^2$ ).<sup>18</sup> That these values were lower than the 20th percentile of total SMI

**Table 3** Multiple regression analysis for the association with skeletal muscle mass index in both sexes

Independent variables	Men Adjusted $R^2$ value = 0.781** standard regression value	Women Adjusted $R^2$ value = 0.627** standard regression value
Visceral fat area ( $\text{cm}^2$ )	$-0.586^{**}$	$-0.627^{**}$
Age (year)	$0.212^{**}$	$0.252^{**}$
Weight (kg)	$1.180^{**}$	$1.169^{**}$

\*\* $P < 0.01$ .

is probably because we did not use the data of SMI in participants aged 80 years and older. Other studies on sarcopenia in Asia also show that the cut-off of SMI is 6.08–7.27 kg/m<sup>2</sup> in men and 4.79–5.80 kg/m<sup>2</sup> in women,<sup>13,33–35</sup> which is quite consistent with the present results. Thus, the 20th percentile of total SMI in men and women in our data can be used for the cut-off of SMI in Asians; however, further studies are required to address whether these cut-off points are associated with adverse health outcomes in Asian older adults.

There were several limitations to the present study that warrant mention. First, physical performance data were not measured. The European Working Group on Sarcopenia in Older People (EWGSOP) has recommended using the presence of both low muscle function (low physical performance or muscle strength) and low muscle mass to diagnose sarcopenia.<sup>36</sup> Therefore, the prevalence of sarcopenia could not be determined. Second, the study design was cross-sectional, and no outcome data are available. Further research with a longitudinal design will be required to clarify whether low muscle mass can predict adverse health outcomes in older Japanese adults. Third, the SMI measurement was estimated using BIA, which is not a method that is recommended by the EWGSOP for assessing muscle mass. However, it is very challenging to measure muscle mass in community-dwelling older adults using dual-energy X-ray absorptiometry (DXA); thus, BIA is a more practical screening method to use in large samples, especially in a community setting. However, to determine the specific effect of an intervention, a more accurate measurement, such as DXA, computed tomography, or magnetic resonance imaging, should be used in future studies. Serum outcomes were not measured. Therefore, the relationship between the SMI and hormone signals could not be determined. Finally, the participants in the present study were limited to visitors to fitness and community centers. Therefore, the participants of this study might not be a representative sample of community-dwelling adults.

In conclusion, the SMI showed an age-dependent decrease in both sexes, and the total SMI decreased by 10.8% in men and by 6.4% in women aged 40–79 years. Notably, age-dependent sex differences were more pronounced in the arm SMI; from 40 to 79 years, the arm SMI decreased by 12.6% in men and 4.1% in women. These results suggest that the age-dependent loss of skeletal muscle mass begins at approximately 40 years-of-age, and becomes prominent after 50 years-of-age in Japanese adults. Furthermore, the visceral fat area showed an age-dependent increase in both sexes, and the visceral fat area increased by 42.9% in men and by 65.3% in women of 40–79 years-of-age. Finally, the SMI was negatively associated with the visceral fat area in both sexes. Thus far, no studies have reported age-dependent changes and the association of muscle mass

and visceral fat in Asian populations. Therefore, the current data could be used as the reference value for Asian adults.

## Acknowledgements

This study was supported by Grants-in-Aid for Comprehensive Research on Aging and Health from the Ministry of Health, Labor, and Welfare of Japan.

## Disclosure statement

The authors declare no conflict of interest.

## References

- Morley JE. Sarcopenia in the elderly. *Fam Pract* 2012; **29**: i44–i48.
- Wang C, Bai L. Sarcopenia in the elderly: basic and clinical issues. *Geriatr Gerontol Int* 2012; **12**: 388–396.
- Cawthon PM, Marshall LM, Michael Y *et al*. Frailty in older men: prevalence, progression, and relationship with mortality. *J Am Geriatr Soc* 2007; **55**: 1216–1223.
- Rolland Y, Czerwinski S, Abellan Van Kan G *et al*. Sarcopenia: its assessment, etiology, pathogenesis, consequences and future perspectives. *J Nutr Health Aging* 2008; **12**: 433–450.
- Topinkova E. Aging, disability and frailty. *Ann Nutr Metab* 2008; **52**: 6–11.
- Janssen I. Influence of sarcopenia on the development of physical disability: the Cardiovascular Health Study. *J Am Geriatr Soc* 2006; **54**: 56–62.
- Kim SH, Kim TH, Hwang HJ. The relationship of physical activity (PA) and walking with sarcopenia in Korean males aged 60 years and older using the Fourth Korean National Health and Nutrition Examination Survey (KNHANES IV-2, 3), 2008–2009. *Arch Gerontol Geriatr* 2013; **56**: 472–477.
- Rolland Y, Lauwers-Cances V, Cournot M *et al*. Sarcopenia, calf circumference, and physical function of elderly women: a cross-sectional study. *J Am Geriatr Soc* 2003; **51**: 1120–1124.
- Lauretani F, Russo CR, Bandinelli S *et al*. Age-associated changes in skeletal muscles and their effect on mobility: an operational diagnosis of sarcopenia. *J Appl Physiol* 2003; **95**: 1851–1860.
- Janssen I, Heymsfield SB, Ross R. Low relative skeletal muscle mass (sarcopenia) in older persons is associated with functional impairment and physical disability. *J Am Geriatr Soc* 2002; **50**: 889–896.
- Baumgartner RN, Koehler KM, Gallagher D *et al*. Epidemiology of sarcopenia among the elderly in New Mexico. *Am J Epidemiol* 1998; **15** (147): 755–763.
- Woods JL, Iuliano-Burns S, King SJ *et al*. Poor physical function in elderly women in low-level aged care is related to muscle strength rather than to measures of sarcopenia. *Clin Interv Aging* 2011; **6**: 67–76.
- Cheng Q, Zhu X, Zhang X, Li H *et al*. A cross-sectional study of loss of muscle mass corresponding to sarcopenia in healthy Chinese men and women: reference values, prevalence, and association with bone mass. *J Bone Miner Metab*. doi: 10.1007/s00774-013-0468-3.

- 14 Lin CC, Lin WY, Meng NH *et al.* Sarcopenia prevalence and associated factors in an elderly Taiwanese metropolitan population. *J Am Geriatr Soc* 2013; **61**: 459–462.
- 15 Pongchaiyakul C, Limpawattana P, Kotruchin P *et al.* Prevalence of sarcopenia and associated factors among Thai population. *J Bone Miner Metab* 2013; **31**: 346–350.
- 16 Lee WJ, Liu LK, Peng LN *et al.* ILAS Research Group. Comparisons of sarcopenia defined by IWGS and EWGSOP Criteria Among Older People: results from the I-Lan longitudinal aging study. *J Am Med Dir Assoc* 2013; **14**: 528.e1–528.e7.
- 17 Ryu M, Jo J, Lee Y *et al.* Association of physical activity with sarcopenia and sarcopenic obesity in community-dwelling older adults: the Fourth Korea National Health and Nutrition Examination Survey. *Age Ageing* 2013; **42**: 734–740.
- 18 Yamada M, Nishiguchi S, Fukutani N *et al.* Prevalence of sarcopenia in community-dwelling Japanese older adults. *J Am Med Dir Assoc* 2013; **14**: 911–915.
- 19 Jackson AS, Janssen I, Sui X *et al.* Longitudinal changes in body composition associated with healthy ageing: men, aged 20–96 years. *Br J Nutr* 2012; **107**: 1085–1091.
- 20 Speakman JR, Westerterp KR. Associations between energy demands, physical activity, and body composition in adult humans between 18 and 96 y of age. *Am J Clin Nutr* 2010; **92**: 826–834.
- 21 Matsuzawa Y. Establishment of a concept of visceral fat syndrome and discovery of adiponectin. *Proc Jpn Acad Ser B Phys Biol Sci* 2010; **86**: 131–141.
- 22 Lira FS, Rosa JC, Dos Santos RV *et al.* Visceral fat decreased by long-term interdisciplinary lifestyle therapy correlated positively with interleukin-6 and tumor necrosis factor- $\alpha$  and negatively with adiponectin levels in obese adolescents. *Metabolism* 2011; **60**: 359–365.
- 23 Schaap LA, Pluijm SM, Deeg DJ *et al.* Higher inflammatory marker levels in older persons: associations with 5-year change in muscle mass and muscle strength. *J Gerontol A Biol Sci Med Sci* 2009; **64**: 1183–1189.
- 24 Song MY, Ruts E, Kim J *et al.* Sarcopenia and increased adipose tissue infiltration of muscle in elderly African American women. *Am J Clin Nutr* 2004; **79**: 874–880.
- 25 Gibson AL, Holmes JC, Desautels RL *et al.* Ability of new octapolar bioimpedance spectroscopy analyzers to predict 4-component-model percentage body fat in Hispanic, black, and white adults. *Am J Clin Nutr* 2008; **87**: 332–338.
- 26 Janssen I, Baumgartner RN, Ross R *et al.* Skeletal muscle cutpoints associated with elevated physical disability risk in older men and women. *Am J Epidemiol* 2004; **159**: 413–421.
- 27 Sattler FR, Castaneda-Sceppa C, Binder EF *et al.* Testosterone and growth hormone improve body composition and muscle performance in older men. *J Clin Endocrinol Metab* 2009; **94**: 1991–2001.
- 28 Thomas DR. Loss of skeletal muscle mass in aging: examining the relationship of starvation, sarcopenia and cachexia. *Clin Nutr* 2007; **26**: 389–399.
- 29 Kitamura I, Koda M, Otsuka R *et al.* Six-year longitudinal changes in body composition of middle-aged and elderly Japanese: age and sex differences in appendicular skeletal muscle mass. *Geriatr Gerontol Int* 2013. doi: 10.1111/ggi.12109
- 30 Baumgartner RN, Waters DL, Gallagher D *et al.* Predictors of skeletal muscle mass in elderly men and women. *Mech Ageing Dev* 1999; **107**: 123–136.
- 31 Harman SM, Metter EJ, Tobin JD *et al.* Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. *J Clin Endocrinol Metab* 2001; **86**: 724–731.
- 32 Prado CM, Wells JC, Smith SR *et al.* Sarcopenic obesity: a Critical appraisal of the current evidence. *Clin Nutr* 2012; **31**: 583–601.
- 33 Lee WJ, Liu LK, Peng LN *et al.* ILAS Research Group. Comparisons of sarcopenia defined by IWGS and EWGSOP criteria among older people: results from the i-lan longitudinal aging study. *J Am Med Dir Assoc* 2013; **14**: 528.e1–528.e7.
- 34 Tanimoto Y, Watanabe M, Sun W *et al.* Association of sarcopenia with functional decline in community-dwelling elderly subjects in Japan. *Geriatr Gerontol Int* 2013; **13**: 958–963.
- 35 Sanada K, Miyachi M, Tanimoto M *et al.* A cross-sectional study of sarcopenia in Japanese men and women: reference values and association with cardiovascular risk factors. *Eur J Appl Physiol* 2010; **110**: 57–65.
- 36 Cruz-Jentoft AJ, Baeyens JP, Bauer JM *et al.* European Working Group on Sarcopenia in Older People. Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in Older People. *Age Ageing* 2010; **39**: 412–423.



## ORIGINAL ARTICLE

# Arterial stiffness is associated with low skeletal muscle mass in Japanese community-dwelling older adults

Ricardo Aurélio Carvalho Sampaio,<sup>1</sup> Priscila Yukari Sewo Sampaio,<sup>1</sup> Minoru Yamada,<sup>1</sup> Taiki Yukutake,<sup>1</sup> Marco Carlos Uchida,<sup>2</sup> Tadao Tsuboyama<sup>1</sup> and Hidenori Arai<sup>1</sup>

<sup>1</sup>Department of Human Health Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan; and <sup>2</sup>Physical Education Faculty, State University of Campinas/UNICAMP, Campinas, Brazil

**Aim:** To examine whether arterial stiffness, measured by the cardio-ankle vascular index (CAVI), is associated with skeletal muscle mass index (SMI) in Japanese community-dwelling older adults.

**Methods:** Data were collected from 175 participants through questionnaires and specific tests; the data included demographic, lifestyle and health characteristics, body mass index (BMI), and body composition features determined by the bioelectrical impedance analysis, ankle-brachial index, the Mini-Nutritional Assessment, handgrip strength (GS), walking speed and shuttle walking tests (SW), and arterial stiffness determined by the CAVI. Absolute SMI was dichotomized according to the first quintile, which determined low ( $n = 35$ ) and normal ( $n = 140$ ) SMI.

**Results:** Participants with low SMI were older ( $P = 0.01$ ), had more polypharmacy ( $P = 0.01$ ), a lower BMI ( $P < 0.001$ ), and fat mass index ( $P = 0.02$ ), and had a greater risk of malnutrition ( $P < 0.001$ ) than the normal group. Additionally, they showed poorer physical performance (GS and SW,  $P = 0.007$  and  $0.01$ , respectively) than the normal group. Furthermore, CAVI was associated with SMI even after adjustments (OR 1.82, 95% CI 1.14–2.90,  $P = 0.01$ ).

**Conclusions:** Our data showed that arterial stiffness is associated with low SMI in community-dwelling older adults, even when adjusting by multiple factors, showing a close interaction of vascular aging and muscle mass decline. *Geriatr Gerontol Int* 2014; 14 (Suppl. 1): 109–114.

**Keywords:** arterial stiffness, cardio-ankle vascular index, older adults, sarcopenia, skeletal muscle mass.

## Introduction

The progressive loss of skeletal muscle mass is the primordial factor to determine sarcopenia, a syndrome that combines low skeletal muscle mass and strength, and can lead to adverse health outcomes, such as physical disability, poor quality of life and mortality.<sup>1</sup> In addition, the elderly might experience several adverse health outcomes as a result of vascular aging, such as increased arterial stiffness, which can contribute to the development of cardiovascular and cerebrovascular diseases.<sup>2</sup> It is known that both the loss of skeletal muscle mass and arterial stiffness worsen with age, and that some of the predisposing factors and mechanisms underlying

low muscle mass and sarcopenia; for example, oxidative stress,<sup>3</sup> inflammation,<sup>4</sup> and insulin resistance,<sup>1</sup> are also associated with atherosclerosis.<sup>5</sup> However, only a few studies have been carried out to verify such associations.<sup>5–8</sup> A study showed that arterial stiffness is associated with an increase in the loss of muscle mass index over time independent of age, body fat, peripheral arterial disease, chronic inflammation, and cardiac disease.<sup>6</sup> Other studies have verified the associations of peripheral lean mass and visceral fat mass with atherosclerosis,<sup>7</sup> and the relationships between regional fat and lean mass and large artery properties in young men and women.<sup>8</sup>

A novel measurement tool to assess arterial stiffness is the cardio-ankle vascular index (CAVI), which reflects the stiffness of the aorta, femoral artery, and tibial artery, and involves the measurement of the brachial-ankle pulse wave velocity (baPWV) and blood pressure (BP). The most important feature of CAVI is its independence from BP during examination,<sup>2,9,10</sup> which shows that it is a useful tool to assess those who are

Accepted for publication 28 September 2013.

Correspondence: Professor Hidenori Arai MD PhD, Department of Human Health Sciences, Kyoto University Graduate School of Medicine, 53 Kawahara-cho, Shogoin, Sakyo-ku. Kyoto 606-8507, Japan. Email: harai@kuhp.kyoto-u.ac.jp



subject to variation in blood pressure at different times of the day, suffer from masked hypertension or are taking antihypertensive medications.<sup>11</sup>

Therefore, the objective of the present study was to examine whether arterial stiffness, measured by CAVI, is associated with skeletal muscle mass index (SMI) in Japanese community-dwelling older adults. We hypothesized that arterial stiffness is associated with a low SMI independent of sex, nutritional status, and physical performance in community-dwelling older adults.

## Methods

The present study had a cross-sectional design.

### Participants

The participants of the present study were community-dwelling Japanese older adults ( $n = 175$ ; male = 84, female = 91) recruited through local press announcements requesting healthy volunteers. Recruited participants were 65 years-of-age or older, and were able to carry out the activities of daily living (ADL) and answer the proposed questionnaires. The exclusion criteria at the first screening were the following: (i) moderate cognitive impairment (i.e. Mini-Mental State Examination score  $\leq 21$  points); (ii) uncontrolled cardiovascular, pulmonary, or metabolic diseases; (iii) any orthopedic conditions that could restrain the ADL; and (iv) comorbidities associated with a greater risk of falls (e.g. Parkinson's disease and stroke). Additionally, in the present study, none of the participants had peripheral artery disease as evidenced by an ankle-brachial index (ABI) of less than 0.9. All participants were informed of the purpose and procedures of the study, and signed a written consent. The data were collected in November 2012.

The study protocol was approved by the Kyoto University Graduate School of Medicine Ethics Committee (No. E1245, E1583).

### Assessments

The participants answered a self-administered questionnaire about demographic, lifestyle, and health characteristics, including age, regular physical activity engagement, alcohol consumption, smoking, current number of medications, and morbidities (i.e. diabetes, hypertension, hyperlipidemia and coronary artery disease; determined by the assumption that the prescribed medications they reported in the analysis were being used for the morbidity).

Additional relevant health indicators, such as (i) body mass index (BMI); (ii) body composition features determined by bioelectrical impedance analysis (Inbody 430;

Biospace, Seoul, Korea); (iii) ABI; and (iv) the Mini-Nutritional Assessment short-form (MNA)<sup>12</sup> were also collected.

The bioelectrical impedance instrument made use of octapolar tactile electrodes, two in contact with the palm and thumb of each hand, and two with the anterior and posterior aspects of the sole of each foot. The participants were instructed to stand with their soles in contact with the foot electrodes and to grasp the hand electrodes. The resistance of the arms, trunk, and legs was measured at frequencies of 5, 50, and 250 kHz. The participants' ID number, height (measured with a standard stadiometer), age, and sex were also inserted in the analyzer. Then, body mass and consequently BMI were automatically measured by the "InBody". For classification purposes, the BMI cut-offs used were those proposed by the Japan Society for Study of Obesity (i.e. underweight, BMI  $<18.5$  kg/m<sup>2</sup>, normal weight, BMI 18.5–25 kg/m<sup>2</sup>, and obese, BMI  $\geq 25$  kg/m<sup>2</sup>).<sup>13</sup> The bioelectrical impedance examination provided values for absolute skeletal muscle mass, body fat percentage, absolute fat mass, and segmental muscle mass (right and left arms/legs and trunk). From these measurements, absolute skeletal muscle mass and absolute fat mass were posteriorly adjusted by height to determine the SMI and fat mass index (FMI), respectively. The "InBody" system uses direct segmental multifrequency technology, and had previously been validated as having a strong correlation to muscle volume and fat mass as measured by dual energy X-ray absorptiometry.<sup>14,15</sup>

Physical performance was investigated by the following: (i) handgrip strength (GS); (ii) walking speed (WS); and (iii) shuttle walking tests (SW).<sup>16,17</sup>

GS was collected with a standard handgrip dynamometer (Smedley's Dynamo Meter; TTM, Tokyo, Japan). The participants were asked to stand up and hold the dynamometer with their arms parallel to their bodies without touching their bodies. GS was measured once for each hand, and the higher value was used to characterize his/her maximum muscle strength. GS was expressed in kilograms (kg).

In the WS test, outside marks of 12 m in length were clearly placed on the ground. Inside this distance, another 10 m long delimitation was marked. The participants were asked to walk the entire distance at their usual pace, but only the time to complete the inner 10 m distance was measured. Such measurement was intended to avoid the acceleration and deceleration stages of the participant's walking.

Finally, the SW test was carried out; two cones were placed 10 m apart. The participants were instructed to walk around the cones without stopping at a pace set by a timed signal played on a CD player. The SW test consists of 102 shuttles divided into 12 levels, each lasting approximately 1 min. The first level consists of three shuttles with a subsequent one-shuttle (i.e. 10 m)

increase at each following level. At each level, the speed is increased by 0.17 m/s, with an initial speed of 0.5 m/s rising to a maximum speed of 2.37 m/s.<sup>16,17</sup> The test ended if the participant was unable to continue (due to breathlessness or any other reason) or was unable to reach the next cone before the timer sounded. If none of these mentioned factors occurred, we stopped the test at shuttle 50 (or 500 m, half of the total) to assure the participants' safety due to fatigue issues. Then, the values in meters were included in the analysis. A resting time of at least 3 min was provided between each assessment, and a longer time was provided if the participant claimed fatigue.

### CAVI

CAVI was determined using VaSera1500 (Fukuda Denshi, Tokyo, Japan). The procedures started with the participants resting for 5 min in a sitting position. Afterwards, they were placed supine on a standard stretcher. Cuffs were wrapped around both arms and ankles to detect the brachial and ankle pulse waves. An electrocardiogram was carried out, and the heart sound was monitored. The pulse wave velocity (PWV) from the heart to the ankle was determined by measuring the length from the aortic valve to the ankle divided by time, according to the heart sound and the rise of the brachial and ankle pulse wave. The BP was measured at the four limbs alternately, first at the right arm and ankle, and then at the left arm and ankle. This procedure is important not only because it reduces the burden of the examinees, but also because it enables a more accurate measurement. Finally, a scale conversion was carried out using the following formula:  $CAVI = a\{2\rho/\Delta P\} \times \ln(Ps/Pd)PWV^2\} + b$  (no unit), in which "ρ" is blood density, "Ps" is systolic blood pressure, "Pd" is diastolic blood pressure, "ΔP" is Ps - Pd, "PWV" is pulse wave velocity, and "a" and "b" are specific constants. This procedure has also been detailed in previous studies.<sup>2,10</sup>

This measurement was carried out once for each participant, and the mean of the right and left values of CAVI for each participant was used for analytical purposes.<sup>18</sup> The validity, reproducibility, and blood pressure-independent nature of this system have been widely documented by other researchers.<sup>2,9,10</sup>

### Statistical analysis

The Kolmogorov–Smirnov test was carried out to determine the normality of the data. Absolute SMI was dichotomized according to the first quintile for males (8.81 kg/m<sup>2</sup>) and females (7.57 kg/m<sup>2</sup>). Then, we arbitrarily assumed that those in the first quintile had a low SMI (*n* = 35), coded 1, and the others were considered normal SMI (*n* = 140), coded 0.

We analyzed the relationship between the two groups using the unpaired *t*-test for the age, BMI, body fat percentage, FMI, and ABI variables, and the Mann–Whitney *U*-test for the SMI, CAVI, GS, WS, and SW tests. Furthermore, the  $\chi^2$ -test was used for sex, regular physical activity engagement, alcohol consumption, smoking, number of medications, morbidities, and malnutrition. In addition, a univariate logistic regression was carried out to verify the association of each variable and the muscle mass condition, except for the number of medications as a result of missing values in the variable; then, a stepwise multivariate logistic regression was carried out to investigate whether CAVI was associated with low SMI. We assigned the status of muscle mass as the dependent variable, CAVI as the main covariate, and sex, age, BMI, MNA, GS, and SW as adjusted covariates. Differences were considered statistically significant at *P* < 0.05. All analyses were carried out using the Statistical Package for the Social Sciences software (SPSS; IBM, Chicago, IL, USA) version 20.0.

### Results

A total of 175 subjects participated in the present study; we divided them into two groups: low SMI older adults (*n* = 35) and normal SMI (*n* = 140) participants. The participants in the first group were older and had more polypharmacy (four or more concurrent medications) than the normal participants. No significant differences were found for the lifestyle characteristics or morbidities (Table 1).

The results of the health indicators showed that low SMI participants had a lower BMI and FMI, and were at a higher risk of malnutrition than the normal group. Additionally, they presented with poorer physical functioning, such as low muscle strength and lower SW test scores. Regarding the CAVI results, the low SMI older adults had higher CAVI (Table 2).

The findings of the multivariate logistic regression showed that females were less likely to have low SMI than males. Similar conditions were verified in the participants with higher BMI and GS. Additionally, CAVI showed an independent association with SMI, even when adjusted for age, sex, BMI, MNA, GS, and SW. Thus, a higher CAVI was associated with low SMI in older adults (Table 3).

### Discussion

The present study supported the hypothesis that arterial stiffness (assessed by CAVI) is associated with low SMI in community-dwelling older adults. Other studies have been carried out to ascertain this association;<sup>5–8</sup> however, none of them considered arterial stiffness as measured by CAVI, a non-invasive and BP-independent tool.

**Table 1** Bivariate comparisons of the participants' demographic and lifestyle characteristics

Variables	Normal ( <i>n</i> = 140)	Low SMI ( <i>n</i> = 35)	<i>P</i>
Age (years)	73 [70–77]	76 [71–78]	0.01
Females	52.1 (73)	51.4 (18)	0.94
Regular physical activity <sup>†</sup>	65.4 (83)	63.3 (19)	0.83
Alcohol consumption <sup>‡</sup>	39.4 (52)	36.7 (11)	0.78
Smoking <sup>‡</sup>	9.1 (12)	6.7 (2)	1.00
No. medications <sup>§</sup>	76.6 (95)	52 (13)	0.01
	23.4 (29)	48 (12)	
Morbidities <sup>‡</sup>			
Diabetes	12.1 (16)	10 (3)	1.00
Hypertension	42.4 (56)	36.7 (11)	0.56
Hyperlipidemia	14.4 (19)	20 (6)	0.41
Coronary artery disease	7.6 (10)	10 (3)	0.71

<sup>†</sup>*n* = 157; <sup>‡</sup>*n* = 162; <sup>§</sup>*n* = 149; values are expressed as medians [interquartile range] or valid percentages (*n*).

**Table 2** Bivariate comparisons of the participants' health indicators

Variables	Normal ( <i>n</i> = 140)	Low SMI ( <i>n</i> = 35)	<i>P</i>
BMI (kg/m <sup>2</sup> )	23.6 ± 2.71	20.7 ± 2.61	<0.001
SMI (kg/m <sup>2</sup> )	9.00 [8.20–9.81]	7.54 [7.39–8.43]	<0.001
Body fat percentage	29.0 ± 7.72	28.1 ± 8.80	0.56
FMI (kg/m <sup>2</sup> )	7.06 ± 2.37	6.03 ± 2.42	0.02
ABI	1.10 ± 0.07	1.08 ± 0.07	0.10
MNA at risk	20.0 (28)	51.4 (18)	<0.001
Handgrip strength (kg)	28.7 [25–35]	24.5 [22.5–31]	0.007
Walking speed (m/s)	1.39 [1.25–1.50]	1.39 [1.22–1.48]	0.48
Shuttle walking (m)	400 [360–470]	360 [300–440]	0.01
CAVI	9.13 [8.52–9.71]	9.57 [8.93–10.4]	0.008

Values are means ± SD, medians [interquartile range] or valid percentages (*n*). ABI, ankle-brachial index; BMI, body mass index; CAVI, cardio-ankle vascular index; FMI, fat mass index; MNA, mini-nutritional assessment; SMI, skeletal muscle mass index.

A previous study investigated the occurrence of a specific association between arterial stiffening (analyzed by baPWV) and peripheral skeletal muscle mass, and concluded that arterial stiffness was associated with a higher loss of muscle mass index over time independent of age, total body fat, peripheral arterial disease, chronic inflammation, or cardiac disease. Ochi *et al.* hypothesized that age-related decline of muscle mass and atherosclerosis share common pathological processes and interact with each other. In fact, the authors verified a direct association with baPWV and thigh muscle sarcopenia in men, but that association was not confirmed in women.<sup>5</sup> Furthermore, Kohara *et al.* found that men with sarcopenic obesity had higher baPWV

than normal, sarcopenic, or obese men.<sup>19</sup> In theory, changes in arterial stiffness might mediate the association between body composition and cardiovascular risk.<sup>8</sup> However, it is unclear how arterial stiffness and the loss of muscle mass relate to each other. Authors suggested that because basal limb blood flow declines with aging, in part due to arterial stiffening, dysfunction in blood vessel dynamics could have a predictive role in muscle mass decline.<sup>6</sup>

Some researchers have linked the higher prevalence of low muscle mass in men<sup>20</sup> to their findings of arterial stiffness in men, but not in women.<sup>5,19</sup> To examine any sex effect on CAVI, we carried out further analysis and verified that men had higher CAVI than women (data

**Table 3** Stepwise multivariate logistic regression considering skeletal muscle mass index (normal or low condition) as dependent variable and cardio-ankle vascular index, age, gender, body mass index, Mini-Nutritional Assessment, handgrip strength, and shuttle walking as covariates

Variables	OR (95% CI)	P
Sex		
Female	0.23 (0.61–0.90)	0.03
BMI	0.71 (0.59–0.85)	<0.001
Handgrip strength	0.83 (0.74–0.94)	0.002
CAVI	1.82 (1.14–2.90)	0.01

Values are odds ratio (95% confidence interval). BMI, body mass index; CAVI, cardio-ankle vascular index; SMI, skeletal muscle mass index.

not shown). However, in our fully adjusted analysis, we verified the association of CAVI and low SMI independent of sex.

Regarding physical performance, those with normal muscle mass presented better physical functioning, such as a higher GS, higher SW test scores, and a lower CAVI, than the group with low SMI. GS is a representative measure of strength and is an important screening tool for sarcopenia,<sup>1</sup> whereas SW represents aerobic capacity.<sup>16,17</sup> Regarding SW, a previous study showed that endurance-trained older men demonstrated lower arterial stiffness than their sedentary age peers despite similar systolic blood pressures, suggesting that age-associated augmentation of arterial stiffness might be mitigated by regular aerobic exercise.<sup>21</sup>

Furthermore, polypharmacy was observed more frequently among participants in the low SMI group. Although we did not deeply investigate the classes of medications to which they were exposed, our results were in agreement with previous studies that identified the association of concomitant medications and impaired physical functioning in older adults.<sup>22</sup>

Based on the present results, we would like to emphasize the importance of physical activity, mainly the combination of progressive resistance exercise and aerobic exercise,<sup>23</sup> in accordance with well-balanced nutrition in relation to low SMI and arterial stiffness, especially because the participants with low SMI in the present study had lower physical performance, lower BMI, and a higher risk for malnutrition. Nutritional status is widely known to be associated with both muscular and vascular health. Thus, aiming to reverse low muscle mass, Yamada *et al.* verified that a diet rich in proteins and vitamin D in combination with resistance exercise was more effective at improving muscle mass than resistance exercise alone.<sup>24</sup> In addition, evidence showed that lower levels of 25-hydroxyvitamin D,

an established marker of vitamin D status, are associated with abnormalities in the indices of arterial stiffness.<sup>25</sup>

Although the low SMI participants had lower BMI and FMI than the normal group, both groups presented similar results for body fat percentage. This result might show that lean body mass is lost, and fat could be preserved or even increased in people with low muscle mass or sarcopenia. As intramuscular and visceral fat increase, and subcutaneous fat decreases with age,<sup>1,4</sup> the association with muscle mass decline and arterial stiffness might also be perceived from the standpoint of the relationship between fat mass and cardiovascular risks.

Some limitations of the present study should be mentioned: (i) its cross-sectional design did not permit the determination of a cause-effect relationship between CAVI and the low SMI condition; and (ii) the small number of participants limited further group subdivision (i.e. to differentiate pre-sarcopenic and sarcopenic older adults) as a result of the low statistical power achieved when further dividing the groups. However, the present study showed that a relationship between CAVI and low SMI does exist, and might serve as a basis for further studies with a larger sample size, analyzing the time effect on muscle, and physical performance decline, and also investigating the role of sex on such an association.

To our knowledge, this is the first study to verify the interaction of CAVI and total SMI in Japanese older adults. The main clinical advantage of the present study was that it clearly showed the important relationship between arterial stiffness and low SMI in community-dwelling older adults as measured by CAVI, a non-invasive reliable method and blood pressure independent measure. It would be useful to perform further health analyses in older adults with arterial stiffness, including body composition features and physical performance measurements, to aid in the early detection of people with the risk of developing sarcopenia; and also to verify arterial stiffness in older adults already in a progressive muscle loss condition. We believe that a suitable intervention for the promotion of improvements in vascular and muscular parameters would be aimed at increasing physical fitness levels and improving nutrition; this combined intervention might reduce the probability of a person developing systolic hypertension and the associated risk of cardiovascular events, and could help maintain SMI and function, especially in older adults.

## Acknowledgments

The present study was supported by Grants-in-Aid for Comprehensive Research on Aging and Health from the Ministry of Health, Labour, and Welfare of Japan.